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Background: Bovine herpesvirus type 1 (BoHV-1) is the causative agent of respiratory and genital tract infections;
causing a high economic loss in all continents. Use of marker vaccines in IBR eradication programs is widely
accepted since it allows for protection of the animals against the disease while adding the possibility of
differentiating vaccinated from infected animals.
The aim of the present study was the development and evaluation of safety and efficacy of a glycoprotein E-deleted
(gE-) BoHV-1 marker vaccine strain (BoHV-1ΔgEβgal) generated by homologous recombination, replacing the viral gE
gene with the β-galactosidase (βgal) gene.
Results: In vitro growth kinetics of the BoHV-1ΔgEβgal virus was similar to BoHV-1 LA. The immune response
triggered by the new recombinant strain in cattle was characterized both as live attenuated vaccine (LAV) and as an
inactivated vaccine. BoHV-1ΔgEβgal was highly immunogenic in both formulations, inducing specific humoral and
cellular immune responses. Antibody titers found in animals vaccinated with the inactivated vaccine based on
BoHV-1ΔgEβgal was similar to the titers found for the control vaccine (BoHV-1 LA). In the same way, titers of inactivated
vaccine groups were significantly higher than any of the LAV immunized groups, independently of the inoculation
route (p < 0.001). Levels of IFN-γ were significantly higher (p < 0.001) in those animals that received the LAV compared
to those that received the inactivated vaccine. BoHV-1ΔgEβgal exhibited an evident attenuation when administered as
a LAV; no virus was detected in nasal secretions of vaccinated or sentinel animals during the post-vaccination period.
BoHV-1ΔgEβgal, when used in either formulation, elicited an efficient immune response that protected animals against
challenge with virulent wild-type BoHV-1. Also, the deletion of the gE gene served as an immunological marker to
differentiate vaccinated animals from infected animals. All animals vaccinated with the BoHV-1ΔgE βgal strain were
protected against disease after challenge and shed significantly less virus than control calves, regardless of the route
and formulation they were inoculated.
Conclusions: Based on its attenuation, immunogenicity and protective effect after challenge, BoHV-1ΔgEβgal virus is
an efficient and safe vaccine candidate when used either as inactivated or as live attenuated forms.
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Bovine herpesvirus-1 (BoHV-1) is an important patho-
gen of cattle and responsible for a wide variety of clinical
diseases, including conjunctivitis and upper respiratory
tract infection known as infectious bovine rhinotrachei-
tis (IBR), reproductive tract lesions, abortion in pregnant
cows, and systemic infection in the newborn [1-3]. In
addition, BoHV-1 has been recognized as an important
component of the bovine respiratory disease (BRD) com-
plex [1,4]. The BoHV-1 infection in cattle is responsible
for considerable economic losses due to decreased milk
production, weight loss and abortion.
The virus genome consists of a linear double-stranded
DNA molecule of about 135.3 kb that encodes for ap-
proximately 70 proteins [5]. Twelve of them (gB, gC, gD,
gE, gG, gI, gH, gK, gL, gM, UL49.5 and Us9) are enve-
lope proteins, of which the first ten are glycosylated [5].
Envelope glycoproteins gE and gI form complexes and
gE is involved in viral intercellular spread (cell-to-cell
spread). BoHV-1 gE open reading frame (ORF) is pre-
dicted to contain 575 amino acid (aa) residues with a 28
aa cleavable signal sequence. The structure of glicopro-
tein E (gE) corresponds to a type I transmembrane gly-
coproteins. The glycoprotein contains three distinct
domains: a 387 aa long hydrophilic extracellular domain
(ecto-domain), a 33 aa long hydrophobic transmembrane
domain and a 125 aa long highly charged cytoplasmic
domain/tegument domain. The mature gE is phosphory-
lated and glycosylated with an apparent molecular mass
of about 92 kD.
Attenuated live viruses or inactivated virions are used
widely as vaccines to control the disease. Thus, BoHV-1-
specific antibodies can be found in bovines on all conti-
nents; its prevalence varies greatly depending on herd size
and management. Classical vaccines complicate serological
diagnosis and determination of the true prevalence of
infection. Marker and conventional vaccines can prevent
disease but not latent infection. Due to the current restric-
tions in international trade for products derived from sero-
positive animals a number of European countries have
eradicated BoHV-1 with very high costs involved. In coun-
tries with a high prevalence of infection, including the
United States, the control of IBR is associated with the
immunization of cattle with marker vaccines. In this con-
text, the ability to differentiate infected from vaccinated an-
imals (DIVA) has become critical issue. Gene-deleted
marker vaccines offer the advantage of deletion of specific
viral genes that are non-essential for viral replication [6,7]
while inducing a substantial protein-specific immune re-
sponse. Currently, vaccines used in BoHV-1 control pro-
grams utilize highly attenuated BoHV-1 strains marked by
a deletion of the gE gene [8]. Glycoprotein E is considered
a virulence factor of all known members of the subfamily
Alphaherpesvirinae [9-11].Live and killed gE-deleted marker vaccines are now
widely used in Europe, in combination with gE-based
diagnostic tests to monitor cattle. The gE-deleted mu-
tants generated thus far include derivations of herpes
simplex virus (HSV), pseudorabies virus, equine herpes-
virus 1 and BoHV-1; these were shown to be attenuated
in mice, swine, foals and calves, respectively [8,9,12,13].
Notably, expression of gE and gI is required for full
pathogenic potential in animals but is not required for
growth in tissue culture [14], thus allowing for it replica-
tion in cell culture. In infected animals, gE is required
for anterograde neuronal spread and neurovirulence. Ac-
cordingly, an interesting safety feature that comes from
using LAV based on gE-deleted viruses is that the virus
cannot spread in an anterograde direction from sensory
neurons in trigeminal ganglia to respiratory mucosa.
Furthermore, gE induces specific antibodies both in the
context of inactivated vaccines or as infectious virus,
thus facilitating serological differentiation of animals im-
munized with a gE-deleted marker vaccine from infected
cattle [7]. Safety and efficacy of both the live and the
inactivated gE-deleted vaccines that are available have
been tested thoroughly [15-22].
In this report, we present data regarding the develop-
ment of a gE-deleted and βgal expressing BoHV-1
(BoHV-1ΔgEβgal) strain and its use as either an inacti-
vated immunogen or as an LAV in cattle. Our results
demonstrate that BoHV-1ΔgEβgal virus is an efficient
vaccine candidate when used either as inactivated or as
live attenuated form.
Methods
Virus and cells
BoHV-1 Los Angeles (LA) (American Type Culture Col-
lection, VR-188) and BoHV-1ΔgEβgal strains were prop-
agated in Madin Darby Bovine Kidney (MDBK) cells
grown in Eagle’s Minimal Essential Medium (MEM),
supplemented with 10% fetal bovine serum (FBS).
Construction of the recombinant plasmid
Virus DNA was extracted from cell-free supernatant
virus preparations following a standard phenol/chloro-
form procedure using sodium dodecyl sulfate (SDS) and
proteinase K lysis, phenol/ether extraction, and ethanol
precipitation [23]. Discrete flanking regions correspond-
ing to gE gene were amplified by PCR from this material.
Primer sequences were based on the published BoHV-1
glycoprotein E (gE) gene sequences [GenBank Accession
Number NC 001847]. Primers were designed to add restric-
tion sites in order to facilitate further cloning. The left
flanking region of gE (L fragment) was obtained using
primers gE1 (5′-GCGAGCAGCGGGAGCGGGGCC-3′),;
and gE2(5′-GGGGCGGATCCGTGGGTTGCA-3′), which
introduced a Sal I and a Bam HI sites, respectively. The
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using primers gE3(5′- AGCTTGGATCCCGGCCGCA
CC- 3′) and gE4 (5′- CCTCAGAATTCGGGGTCTC
GG- 3′), which introduced a Bam Hi and an EcoR I sites
to amplified fragment, respectively.
DNA fragments corresponding to the left (L) and right
(R) gE flanking regions obtained by PCR were digested
with the appropriate enzymes and cloned sequentially into
the pUC19 vector (Clontech). First, the L product (734 bp
long, corresponding to position 120956 to 121714 of the
BoHV-1 genome) was cloned between the SalI and BamHI
sites (recombinant plasmid pUCL), and then the R prod-
uct (632 bp long, corresponding to position 123375 to
124008 of the BoHV-1 genome) was cloned between the
BamHI and EcoRI sites (recombinant plasmid pUCLR),
using a BamHI site that linked both L and R fragments.
The blunt 4.5 kb fragment, which contains the bacterial
β-gal gene under the control of the human cytomegalo-
virus immediate early promoter (HCMV-IE), was inserted
into the blunted BamHI site of pUCLR. The resulting gE-
deletion/β-gal insertion plasmid (pUCLRβ-gal) carried a
deletion of 1,640 bp of BoHV-1 DNA, and the insertion of
the β-gal gene controlled by the human cytomegalovirus
immediate early promoter. In pUCLRβ-gal, the β-gal gene
is flanked by virus-specific sequences required for recom-
bination with the viral DNA: a 734 bp upstream sequence
(L) containing part of the gE promoter and the first 23 bp
of the coding sequence, a 632 bp downstream sequence
(R) containing the last 67 bp at the 3′ extreme, and the
complete ORF of the US9 gene (474 bp). Identity of both
fragments corresponding to L and R were confirmed by
sequencing (Fmol, Promega) (data not shown).
Generation of recombinant BoHV-1 gE-deleted βgal
(BoHV-1ΔgEβgal) virus
To generate the BoHV-1 gE-deleted recombinant virus,
MDBK cells were co-transfected with a ScaI linearized
pUCLRβ-gal plasmid DNA together with a full-length
DNA derived from BoHV-1 LA strain. Briefly, a mixture
of 2 μg of parental BoHV-1 LA DNA, 0.2 μg of ScaI lin-
earized pUCLRβgal vector and 16 μl of Lipofectamine
(Gibco BRL, Life Technologies) was added onto a 60%
confluent MDBK cell monolayergrown in a 6-well plate,
and then incubated for 8 hours at 37°C in a CO2-con-
trolled atmosphere. A media change was then performed
using MEM containing 5% FBS and the plates were in-
cubated for 16 hours in the same conditions described
above. Each transfected cell monolayer was trypsinized
and transferred to a 25 cm2 flask containing 5% FBS
MEM and incubated until cytopathic effects (CPE) were
observed. To determine the dilution of the inoculum for
the Bluo-gal screening assay, the co-transfection prod-
ucts were titrated by plaque forming units (PFU) and
frozen until the screening assay was performed.Purification of the recombinant virus
Co-transfection products were examined for their β-gal
expression by histochemical staining of infected cells.
The recombinant viruses able to form blue plaques in
the presence of the β-galactosidase substrate (haloge-
nated indolyl-β-D-galactoside) were plaque purified five
times under an agar overlay [24]. Recombinant viruses
expressing β-gal activity were selected by the appearance
of blue plaques.
Molecular characterization of the recombinant virus
The recombinant virus was further characterized by
PCR (gE-specific primers: gE7: 5′-CGCCCGTCTTT
CTCCCAG-3′ and gE8: 5′-GCGGGACGAGGAGAGG
GA-3′) and by Southern blot analysis targeting a part
of the gE ORF. Lack of gE protein expression in BoHV-
1ΔgEβgal infected cell lysates done by Western blot.
Southern blot hybridization
Genomic DNA extracted from purified wild-type and re-
combinant BoHV-1 viruses were digested with HindIII
and the corresponding fragments were separated by
electrophoresis in a 0.6% agarose TBE gel, then trans-
ferred to a nitrocellulose membrane (Zprobe, Bio-Rad).
[25]. The membrane bearing the immobilized DNA frag-
ments was blocked with 2x SSC solution and fixed by
heating at 80ºC for 30 minutes. Hybridization was per-
formed separately with three specific probes (L, R, y gE)
previously obtained by PCR and labeled with 32S
(Prime-a-Gene Labeling System, Promega).
gE-specific immunoblot analyses
Polyacrylamide gel electrophoresis in the presence of
SDS (SDS-PAGE) and additional immunoblot analyses
were performed using mock and virus-infected cells.
Briefly, either mock (non-infected MDBK cells) and
virus-infected cells were concentrated by ultracentrifuga-
tion at 12,000 g for 1 h at 47°C, resuspended in sample
buffer (50 mM Tris–HCl, pH 7.5, 1 mM PMSF, 8 M
urea, 1% SDS, 2 mM DTT and 2% β-Mercaptoethanol),
boiled for 10 minutes, separated by gel electrophoresis
in 12.5% polyacrylamide gels and blotted on to Immobi-
lon P membranes (Millipore). Membranes were blocked
overnight in phosphate buffered saline and 0.05% Tween
20 (PBST) containing 5% skim milk (all subsequent steps
were performed using this buffer). Then, they were incu-
bated for 2 hours at 37°C with the corresponding mo-
noclonal antibodies: anti-gE, MAb3 (kindly provided by
Dr. J.T. Van Oirschot from the Institute of Animal
Science and Health, Lelystad, Netherlands), or anti-gD
(kindly provided by Dr. L.A. Babiuk from the Vaccine
and Infectious Disease Organization, University of Sas-
katchewan, Saskatoon, Saskatchewan, Canada). After
three washes with PBST, membranes were incubated
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serum (KLP Inc) for 1 hour at 37°C. After washing three
times, antibody binding was visualized by chemilumin-
escence (Renaissance kit, NEN Life Science) after ex-
posure to an X-ray film (CurixOrto ST-G2, AGFA).
Virus growth kinetics
The growth kinetics of the BoHV-1ΔgEβgal strain in
MDBK cells was compared to that of the parental
BoHV-1 LA strain. A series of replicate cultures of
MDBK cells were infected separately with a MOI of 0.1
per cell of recombinant BoHV-1ΔgEβgal or the parental
BoHV-1 LA strain. Infected cultures were harvested at
successive post-infection intervals and frozen in aliquots
until titration. Virus titration was performed by the end-
point dilution method of Reed & Muench, in three in-
dependent repetitions.
Inactivated vaccine formulation
BoHV-1 LA or BoHV-1ΔgEβgal were propagated accord-
ing to the conditions described earlier [26]. Preparations
were inactivated by treatment with 1% (v/v) 0.1 M binary
bromoethylenimine (BEI) for 25 h at 37°C. One volume of
inactivated virus suspension was mixed with one volume
of INTA mineral oil adjuvant (formulated with Arlacel C,
Markol 52 and Tween 80), to produce a water-in mineral
oil emulsion according to Smitssart et al. [27].
Vaccination experiments
The animal experiments reported in this manuscript
have been performed following internationally recog-
nized guidelines with the approval of the Institutional
Committee for Care and Use of Experimental Animals,
CICUAE-CICVyA. INTA, Argentina.
Vaccination experiments were performed using 12 to
18 month-old Holando and Angus × Hereford calves
with undetectable BoHV-1 serum antibodies (evaluated
by ELISA and virus neutralization tests).
All challenge experiments using virulent BoHV-1 LA,
and inoculations using attenuated BoHV-1ΔgEβgal (dose:
108.25 TCID50/mL) were performed in a type II biosafety
animal facility.
Viral challenge was performed using 2 ml virulent
BoHV-1 LA (107.5 TCID50/ml) into each nostril, by in-
tranasal inoculation (IN) with an ultrasonic nebulizer
(ELECTROLAB AP-300).
Evaluation of BoHV-1ΔgEβgal as either inactivated and
attenuated vaccines
Table 1 shows the experimental design describing number
of animals, vaccination date and route, date of challenge,
date of BoHV-1 specific antibodies determination, BoHV-
1 excretion in nasal fluids, date of lymphoproliferative
response.Safety assessment for BoHV-1ΔgEβgal as a life attenuated
vaccine
The safety test was performed in pregnant cows. Five
pregnant cows (being in the third to sixth month of
pregnancy) were IV infected with attenuated BoHV-
1ΔgEβgal virus (4 ml of the viral suspension with a titer
of 108.25 TCID50/ml). Animals were clinically observed
until they gave birth and serologically evaluated until
370 dpv. Likewise, newborn calves were also evaluated
in regards to their clinical and immune conditions, as
well as the virus shedding.
Detection of virus neutralizing antibodies
Virus neutralization (VN) was performed using primary
fetal bovine testis (FBT) cell cultures in 96-well microti-
ter plates using the constant virus-variable serum
method [26,27]. Each dilution was tested in four wells
containing FBT cell monolayers an adsorbed for 1 hour,
the unabsorbed virus was removed and MEM with 5%
FBS, was added. Plates were then incubated for 3 days at
37°C and the number of wells and serum dilution show-
ing cytopathic effect was scored. Log10 of the reciprocal
value of the highest serum dilution in which CPE was
prevented was considered the virus neutralization titer.
Detection of anti-BoHV-1 and anti-gEantibodies in serum
Total antibodies against BoHV-1 in bovine serum were
measured by an indirect ELISA as described elsewhere
[28]. Titers for bovine sera were expressed as Log10 of
the reciprocal of the highest serum dilution which gives
readings of absorbance greater or equal to 40% of the
positive control measuring at an OD of 405 nm. Detec-
tion of gE-specific antibodies was performed using a
commercial ELISA for BoHV-1 that allows for the detec-
tion of gE-specific antibodies (HerdChek Anti-IBR gE/
IDEXX Laboratories), according to the manufacturer’s
directions.
Detection of IgG1/IgA antibodies in nasal swabs
The mucosal immune response was determined using a
specific ELISA for the detection of IgG1 and IgA. Briefly,
nasal swabs were collected and frozen at −80°C. The anti-
gen was prepared as described before (Romera et al., [26]).
BoHV-1-specific lymphoproliferation assay
Whole blood samples were collected by venipuncture in
syringes containing heparin. Lymphocyte-enriched cells
were isolated from the buffy coat as described elsewhere
[26] by centrifugation on Lymphoprep (Nycomed Pharma
A.S.). Cells were washed twice in RPMI + 5% FBS. UV
light-inactivated suspensions of virus-infected MDBK cells
(5 μg/ml) and control MDBK cells were used as antigens.
The corresponding inactivated antigen was added to a
100 μl volume of medium containing 2 × 105 lymphocytes,
Table 1 Experimental design
Experiment Vaccine # animals Vaccination time
(dpv) [route, vol.]
Challenge
(dpv)
BoHV-1
antibodies (dpv)
BoHV-1 sheeding
(dpv/dpc)
LPT
(dpv/dpc)
inactivated
BoHV-1ΔgEβgal vaccine
BoHV-
1ΔgEβgal
5 0, 21 [SC, 3 ml] 186 0, 14, 21, 30, 67,
150 and 186
0, 3, 5, 7, 8, 10, 12,
14, 17 and 22 dpc
7,72 dpv
BoHV-1LA 5 0, 21 [SC, 3 ml] 186
mock 6 186
attenuated
BoHV-1ΔgEβgal vaccine
BoHV-
1ΔgEβgal
5 Group 1: 0 [IN, 4 ml] 42 0, 7, 19, 34 and 42 1 to 42dpv 7,30 dpc
5 Group 2: 0 [IM, 4 ml] 42 and
Sentinel 5 Group 4 3, 5, 7, 8, 10, 12, 14,
17 and 22 dpc
Mock 5 Group 5 42
attenuated
BoHV-1ΔgEβgal
vaccine SAFETY
BoHV-1ΔgEβgal 5 Group 3: 0 [IV, 4 ml] along 370
SC: subcutaneous, dpv: days post-vaccination; dpc: days post-challenge.
During the next 42 days post- vaccination with attenuated BoHV-1ΔgEβgal, viral excretion was controlled, as well as clinical signs such as loss of appetite, lesions
of nasal, ocular and oral mucosae and discharge from the nose or eyes and rectal temperature. General clinical status was evaluated and recorded using a rating
system (ranging from 0 = asymptomatic to 3 = severe symptoms). Nasal swabs were scored as follows: 0 = absent, 1 = slightly serous, 2 = severely serous,
3 = seromucous, 4 =mucopurulent.
Romera et al. BMC Veterinary Research 2014, 10:8 Page 5 of 12
http://www.biomedcentral.com/1746-6148/10/8performed in triplicate in a 96-well plate format. One
microgram of the mitogen Concavalin A (Sigma, St Louis,
USA) was added to the positive control wells. The
lymphocyte cultures were incubated for 4 days at 37°C in
a humidified atmosphere containing 5% CO2. Twenty
hours before harvesting, 4 μCi of [3H] tymidine was added
to each well. Cell proliferation was measured as [3H] tymi-
dine uptake in a scintillation counter (LKB, Wallac, 1219
Rackbeta) and results were obtained as counts per minute
(CPM). The values are the mean of the triplicate values and
are expressed as stimulation index (SI), where SI =mean
CPM of antigen-stimulated lymphocytes/mean CPM of
MDBK-stimulated lymphocytes). A threshold value of
SI = 3 was established.Interferon Gamma assay
The capacity of mononuclear cells to secrete interferon
γ (IFNγ) in response to a specific in vitro stimulation
with inactivated BoHV-1 viral antigen was evaluated
by a indirect sandwich ELISA. Briefly, 1.5 × 106 mono-
nuclear cells were diluted in 100 μl of RPMI 10% FBS
per well, in sterile microplates of 96 “U” bottom wells.
The supernatant was added on Immulon II microplates,
previously sensitized ON with anti bovine IFNγ mono-
clonal antibody (mAbs), and blocked with PBST 0.1%
BSA. A reference curve was performed using IFNγ
standard at known concentrations. Detection of the
captured IFNγ was done using a rabbit anti-bovine
IFNγ serum, diluted in 0.1% PBST-BSA. In order to im-
prove the sensibility of the assay, plates were later incu-
bated with biotin-labeled rat anti-rabbit IgG and
developed using disodium p-nitrophenyl phosphate(PPN) as substrate. Optical densities (OD) at A405 were
measured 25 minutes after the addition of the substrate.Statistical analysis
Comparison of the vaccine profiles obtained throughout
the experimental period was performed using an analysis
of variance (ANOVA) for repeated measures with the
Greenhouse and Geisser correction of the significance
levels (fixed at 5%). The post-ANOVA comparisons were
performed using the Bonferroni test with the same level
of significance. All the statistical calculations were per-
formed using the SAS program (release 6.04), following
the G.M.L. procedure [29].Results
Construction of a gE deletion vector
The gE gene of BoHV-1 is located between BoHV-1 gen-
ome nucleotide positions 121714 and 123440, within the
US region (Figure 1a), similarly to other alphaherpes-
viruses. The BoHV-1 gE gene is flanked upstream by the
gI (US7) gene and downstream by the BoHV-1 homologue
of the herpes simplex virus (HSV-1) US9 gene [30,31]
(Figure 1b). Based on the position of the gE ORF, a gE de-
letion recombinant vector, pΔgEβgal, was constructed and
composed of two DNA fragments flanking the gE coding
region (pUCLRβgal), created by PCR amplification of viral
DNA from the BoHV-1 LA parental strain (Figure 1d).
The upstream flanking fragment is a SalI/BamHI 734 bp
region (L) covering from position 120956 to 121714 of the
BoHV-1 genome while the downstream fragment is a
BamHI/EcoRI 632 bp region (R) covering from position
123375 to 124008 of the BoHV-1 genome (Figure 1c). The
Figure 1 Molecular structure of BoHV-1ΔgEβgal virus. (a) Target region for the gE deletion in BoHV-1 genome. (b) gE ORF (US8) is flanked by
gI (US7) and US9 genes. (c) Primers gE1 and gE2 were designed to amplify the left (L) fragment, and primers gE3 and gE4 were designed to amp-
lify the right (R) fragment. The sequences of primers gE2, gE3 and gE4 were designed in order to create the depicted restriction sites to facilitate
the cloning strategy. (d) pUCLRβgal recombination vector diagram restriction sites used for cloning and relative position of the elements decribed
are shown (e) Confirmation gE-specific deletion by PCR. Lanes 2–4 primers specific to the gE sequence (gE7 and gE8) were used. Different templates
were used for each lane shown: Lane 2 negative control (ultrapure sterile water); lane 3 BoHV-1ΔgEβgal DNA; lane 4 parental BoHV-1 LA DNA; lanes 1
molecular weight marker (100pb, Promega). (f) Molecular characterization of the recombinant BoHV-1ΔgEβgal strain. Southern blot analysis for
gE gene. Viral DNA from BoHV-1ΔgEβgal (lane 1) and from parental BoHV-1 LA strain (lane 2) were digested with HindIII restriction enzyme,
separated by 0.6% agarose gel electrophoresis, blotted to a membrane and probed with the gE probe. (g) Western blot for gE protein. Concentrated
virus (BoHV-1ΔgEβgal, lane 1; and parental BoHV-1 LA, lane 2) was separated by electrophoresis in a 12% SDS-PAGE, blotted to a membrane and
incubated with specific serum. Panel (i) gE-specific monoclonal antibody, panel (ii) gD-specific monoclonal antibody.
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construct.
Development of a BoHV-1 gE-deleted virus mutant
(BoHV-1ΔgEβgal)
To generate the gE deletion mutant virus, the recombin-
ant vector pUCLRβgal was co-transfected with BoHV-1LA DNA into MDBK cells. The first screening was based
on βgal expression. Selected viruses (blue plaque +) were
further evaluated by PCR amplification using specific
primers for gE regions (Figure 1e). The intended gE gene
deletion and insertion of the βgal gene at the gE locus was
further confirmed by Southern blot analysis with a gE-
specific probe (Figure 1f). The absence of the 1639 bp gE
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ment with the anticipated size of 4.5 kb demonstrated that
the intended recombination had taken place in a site-
specific manner. Western blot analysis using a BoHV-1
gE-specific MAb3 confirmed the deletion of the gE pro-
tein in the BoHV-1ΔgEβgal virus while a 92- to 95-kd
BoHV-1 gE product was detected in BoHV-1 cell extracts
(Figure 1g). The L and R fragments of BoHV-1ΔgEβgal
were sequenced. No difference with wt virus were found.
Growth properties of the BoHV-1gE deletion mutant
virus, BoHV-1ΔgEβgal, were compared with the BoHV-1
LA strain in a multistep growth curve performed using
MDBK cell cultures infected at a MOI of 0.1. Virus
yields were determined by titration performed using
MDBK cells. No significant differences were detected be-
tween the titers achieved with wt BoHV-1 strain and the
gE-deleted strain (Figure 2).
Assessment of BoHV-1ΔgEβgal virus as an inactivated
vaccine
Animals (n = 5/group) were subcutaneously vaccinated
at days 0 and 21 with either a vaccine formulated with
BoHV-1ΔgEβgal or wild-type BoHV-1 LA strain. At 186
dpv, the two vaccinated groups and a mock-vaccinated
group (n = 6) were IN challenged with 107.5 TCID50/ml
virulent BoHV-1 LA strain by aerosol exposure.
Total BoHV-1-specific antibody responses in animals
immunized with the BoHV-1ΔgEβgal inactivated vaccine
did not differ significantly from those of bovines vacci-
nated with BoHV-1 LA virus (Figure 3b). Antibody titers
were first detected at 14 dpv, with highest levels reached
at 30 dpv (approximately 4.0) in both vaccinated groups.
Similarly, neutralizing antibodies were first detected in
vaccinated bovines at 30 dpv, (titers of 2.04 and 1.8 forFigure 2 Growth kinetics of the BoHV-1ΔgEβgal virus. MDBK
cells were infected at a MOI of 0.1 with either BoHV-1ΔgEβgal or
BoHV-1 LA virus strains. Viral replication was checked every 3 hours
during a period of 60 hours pi. Virus titrations were performed in
duplicate for each time point on MDBK cells. Titers are expressed as
TCID50/ml. Each data point represents the mean of the titers obtained.BoHV-1ΔgEβgal-immunized and BoHV-1 LA-immunized
groups, respectively). The neutralizing antibody titers be-
fore challenge ranged between 1.2 and 1.1 (Figure 3a). No
significant differences were found in the responses elicited
by BoHV-1ΔgEβgal and BoHV-1 LA as inactivated anti-
gens. Nasal swabs were analyzed for isotype profiles of the
virus-specific antibody responses at the time of challenge.
We found that 5/5 animals vaccinated with BoHV-1 and
4/5 animals vaccinated with BoHV-1ΔgEβgal exhibited
anti-BoHV-1 IgG1 antibodies in nasal swabs (titer = 1.6),
while no IgA antibodies were detected in the same sam-
ples (data not shown).
Assessment of the gE-specific antibody response could
be effectively utilized to differentiate animals vaccinated
with inactivated BoHV-1ΔgEβgal, inactivated BoHV-1
LA, as well as those infected with BoHV-1 LA virus. At
14 dpv, groups that were BoHV-1ΔgEβgal-vaccinated,
mock-vaccinated, or sentinel animals were found to be
negative for gE-specific antibodies. However, these ani-
mals developed anti-gE antibodies by 216 dpv, 30 days
after challenge. Additionally, gE-specific antibodies wereFigure 3 Antibody response to BoHV-1 observed in vaccinated
cattle. BoHV-1-specific antibody response detected by ELISA (b) or
virus neutralization assay (a) in animals vaccinated either with
inactivated (I) or live attenuated vaccine (L) formulated with
BoHV-1ΔgEβgal or BoHV-1 LA viruses. Live attenuated vaccines were
administered by intranasal (in), intramuscular (im) or intravenous (iv)
route. Neutralizing antibody titers are expressed as log10 of the
reciprocal value of the serum dilution giving protection to CPE. Averages
and SEM of the titers obtained for each group are shown for each time
point. Antibody titers measured by ELISA are expressed as log10 of the
reciprocal value of the serum dilution giving an A405 of 40% of the
positive control. Each point represents the mean titer and SEM of
five animals.
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LA strain at 14 dpv and were also positive by the end of
the experimental period (data not shown).
Cellular immune responses, detected by LPT and IFNγ
production specific to BoHV-1 are shown in Figure 4.
Animals produced a positive LPT (SI ≥ 3) in the BoHV-
1ΔgEβgal group while a LPT response >3 was detected
for one of the BoHV-1 LA-vaccinated animals. No sig-
nificant differences were found in the responses elicited
by BoHV-1ΔgEβgal versus BoHV-1 LA when adminis-
tered as inactivated antigens, and none of the bovinesFigure 4 Cellular response to BoHV-1 observed in vaccinated
cattle. Cellular immune response at 7 dpv detected by (a)
Lymphocyte proliferation test (LPT). Values are expressed as the
percentage of animals in each treatment group exhibiting significant
(LPT response >3) lymphocyte proliferation after vaccination at 7
dpv. (b) IFNγ at 7dpv. Values are expressed as pg/ml. References in
this figure are as described in Figure 3.belonging to the sentinel or mock-vaccinated groups
showed positive reactions throughout the duration of
the experiment (Figure 4a). Only low levels of IFNγ
could be detected in the inactivated-vaccinated group
during the evaluated period (Figure 4b).
Clinical monitoring of animals was performed daily,
starting the day of vaccination until the end of the post-
challenge observational period. No animals exhibited
signs of BoHV-1 disease after vaccination. Bilateral nasal
serous discharge was detected in the BoHV-1ΔgEβgal
group at 2 days post-challenge (dpc) and for 11 days
virus shedding was detected, with a maximum mean
titer of 1.3 TCID50/ml at 8 dpc. In the BoHV-1 LA
group, nasal discharge was mucous or serous. Virus
shedding in mock-vaccinated animals peaked at 8 dpc
(6.1 TCID50/ml) and serous to mucous nasal discharge
lasted approximately 2 weeks. The protective responses
were statistically different (p < 0.001) between vaccinated
vs. mock-vaccinated animals, while no significant differ-
ences were found between animals vaccinated either
BoHV-1ΔgEβgal or BoHV-1 LA.
Assessment of efficacy BoHV-1ΔgEβgal virus as a live at-
tenuated vaccine
Animals involved in this assessment were randomly al-
lotted into five groups of five cattle each. Groups 1, 2
and 3 received 4 ml of 108.25 TCID50/ml of BoHV-
1ΔgEβgal virus by the IN, IM and IV routes, respect-
ively. Group 4, the sentinel group, did not receive vac-
cine or challenge virus, but was housed with vaccinated
animals beginning at 3 dpv, to evaluate horizontal trans-
mission. Group 5 consisted of mock-vaccinated calves.
BoHV-1ΔgEβgal virus was shown to be attenuated. All
animals vaccinated with BoHV-1ΔgEβgal, regardless of
the inoculation route, exhibited minimal clinical symp-
toms of infection, with serous rhinitis as the only ob-
served indicator of disease. No apathy, depression or
loss of appetite was observed in these calves and their
body temperatures never exceeded 40°C. Additionally,
no detectable BoHV-1ΔgEβgal virus was found in the
nasal or ocular secretions of the vaccinated calves. Only
two animals belonging to the IN group shed virus, with
viral titers of 1.5 TCID50/ml at 3 dpv, likely due to the
existence of residual virus from the vaccination. No virus
shedding was detected in the sentinel animals.
Analysis of the antibody response in animals vacci-
nated with BoHV-1ΔgEβgal indicated that detection of
antibodies, measured by ELISA, started at 19 dpv in
those vaccinated either IM or IV, while those vaccinated
IN began exhibiting detectable antibody responses at 34
dpv, with significantly lower titers (p < 0.001) compared
to the IM- and IV-vaccinated groups. On the day of
challenge (42 dpv), the average antibody titers were 0.7
(±1.2) in the IN-vaccinated group and 2.36 (±1.2) and
Figure 5 Values of virus shedding (a) and rhinitis severity (b) in
vaccinated cattle after challenge. Virus shedding titers are
expressed as log10 TCID50 per ml nasal fluid. (b) Each point in the
graph is a average and SEM of the score taken in all the animals of
each group. Rhinitis severity is score as follows: 0, absence; 1, slightly
serous; 2, severely serous; 3, seromucous; 4, mucopurulent.
References in this figure are as described in Figure 3.
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ively (Figure 3b). After challenge, antibody levels in-
crease for all groups, reaching their maximal levels at 56
dpv with values of 3.7 (±0.3) for the IN-vaccinated group
and 3.88 (±0.26) for the IM-vaccinated group (data not
shown). While in the mock-vaccinated group animals
displayed average antibody titers of 3.04 (±0.29) at 30 dpc,
no antibodies were detected during the entire post-
vaccination period in the sentinel group. Antibody re-
sponses were statistically different (p < 0.001) between IM/
IV- vs. IN-vaccinated groups, and between vaccinated vs.
mock-vaccinated animals, while no significant differences
were found between animals vaccinated either IM or IV.
In agreement to the presence of total BoHV-1 anti-
bodies, detection of virus neutralizing antibodies (VN)
started at 19 dpv in animals vaccinated IM and IV. Ti-
ters found for IM and IV groups were significantly
higher than in the IN-vaccinated group (p < 0.001). No
VN titers were detected in the IN-vaccinated, mock-
vaccinated or sentinel groups (Figure 3a).
At 14 dpv, all three groups of animals vaccinated with
BoHV-1ΔgEβgal were found negative for presence of gE
specific antibodies. After challenge with BoHV-1 LA
strain, only animals from two vaccinated groups (IN and
IM) turned to be positive for the presence of gE-specific
antibodies.
The BoHV-1 specific T lymphocyte stimulation was
evaluated using the LPT. At 7 dpv, the percentages of
calves with a positive response to the LPT assay
depended on the infection route. In the BoHV-1ΔgEβgal
IN group, all calves produced a positive LPT response,
while 60% and 20% of the IM- and IV-vaccinated groups
were positive responders, respectively (Figure 4a). At 72
dpv (30 dpc), a positive response was seen in 80% of the
calves in the IN-vaccinated group, and in 40% of the
IM-vaccinated group (data not shown). The results of
IFNγ production were in agreement with the data ob-
tained with the LPT. When the production of IFNγ was
evaluated at 7 dpv the calves that received the vaccine
by IN spray demonstrated greater levels of IFNγ com-
pared to those which received the IM vaccine (Figure 4b).
The levels of IFN-γ were significantly higher (p < 0.05)
in those animals that received the live virus vaccine by
IM and IN routes, than those receiving the inactivated
virus vaccine. Surprisingly, no detectable INF-γ response
was found for the group vaccinated via IV.
Virus shedding titers during the post-challenge period
of BoHV-1ΔgEβgal-vaccinated animals were significantly
lower (p < 0.001) than in mock-vaccinated animals.
Virus shedding of animals vaccinated via IN- and or IM
showed maximum individual titers of approximately
105.5 TCID50/ml. Mock-vaccinated calves shed virus for
a period of 13 days and exhibited high individual titers
(106.6 TCID50/ml) (Figure 5a).Clinical analysis of the mock-vaccinated animals dem-
onstrated the presence of symptoms, characterized by
bilateral serous rhinitis observed at 2 dpc that increased
in severity, as manifested by severe seromucous rhinitis
(score 2–4) by 8–11 dpc, returning to normal by 22 dpc.
All vaccinated animals, regardless of the route of inocu-
lation, displayed significantly less severe symptoms, suf-
fering slight serous rhinitis (score 1 to 2) or absence of
rhinitis (score 0) (p < 0.001) in comparison with the
mock-vaccinated group (Figure 5b). No apathy or loss of
appetite was registered in the vaccinated animals.
Safety of BoHV-1ΔgEβgal LAV in pregnant animals
The pregnant cows that received the BoHV-1ΔgE-βgal
virus by the IV route did not present abortions and all
reached labor successfully. Animals only presented a
transient and slight symptom manifestation of after the
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of body temperature. All the births reached term and
none of the newborn calves showed detectable viral ti-
ters in their nasal secretions. Since their ninth day of life,
we were able to detect in blood serum a titer of 1.6 of
specific antibodies against BoHV-1 indicating the ab-
sorption of specific immunoglobulins from the maternal
colostrum. BoHV-1ΔgE-βgal was shown to be com-
pletely innocuous not causing adverse collateral effects
abortions/mummifications. Pregnant cows showed
BoHV-1 specific antibody titers (≥ 1.6) until day 370 pv
(data not shown). In addition, the LAV inoculated by IV
route (group 3) induced long term immunity, since anti-
bodies were detected during up to 370 days after a single
immunization.
Discussion
We describe here the development of a βgal-expressing
gE-mutated BoHV-1 strain (BoHV-1ΔgEβgal). We char-
acterized the use of BoHV-1ΔgEβgal as an immunogen
in the formulation of both inactivated and LAV against
BoHV-1. It is shown that BoHV-1ΔgEβgal, when used in
either formulation, elicits an efficient immune response
that protects animals against challenge with virulent
wild-type BoHV-1. Importantly, antibody responses in-
duced by BoHV-1ΔgEβgal virus (inactivated or live) can
be serologically distinguished from those induced by
wild-type virus, even at long term time-points after be-
ing exposed to infectious virus (30 dpc).
The viral gE ORF in BoHV-1ΔgEβgal was completely
removed with the exception of the first 23 bp in its 5′
end and the last 67 bp in its 3′ end, and the β-gal gene
was inserted in its place. Thus, BoHV-1ΔgEβgal differs
from the mutant virus previously described by van Enge-
lenburg et al., which carries a deletion of the complete
gE gene based on the Lam strain [9]; from the mutant
described by Rebordosa et al. [10] and from the recom-
binant strain developed by Chowdhury et al. that con-
tains 372 of the 575 aa of gE [32].
The βgal marker gene was chosen to be incorporated
in the genome in order to facilitate the identification of
the virus both for selection of recombinant clones and
for the potential use in identification of the agent in
samples derived from vaccinated animals. Removing the
whole gE ORF constitutes a safety feature of the novel
BoHV-1ΔgEβgal strain which also resulted in virulence
attenuation. Due to the length of the insert, the addition
of a βgal expressing cassette (4.5 kb) reduces to the
minimum the probability of reversion to wild type forms
of the BoHV-1.
Despite efforts made to generate a revertant, we were
not able to obtain one from BoHV-1ΔgEβgal. Thus, the
parental strain BoHV-1 LA was used as control for all
vaccination experiments.The vaccination schedule followed for testing efficacy
for the inactivated vaccines was based on the official
schedule of vaccination using inactivated vaccines against
IBR disease (National Sanitary Service, SENASA). The
official schedule mentioned involves first vaccination and
a booster immunization after 21 days. It is known that
6 months after immunization with an inactivated BoHV-
1 vaccine, virus-specific antibodies drop to a minimum
value. In order to work with the maximum astringency,
the calves were maintained and monitored during
6 months until challenge. On the other hand, manipula-
tion of animals immunized using a LAV is considered a
biohazard by the official authorities (National Advisory
Commission of Agronomic Biotechnology, CONABIA).
Thus, the experiments should be performed in closure
and only after obtaining the corresponding authorization.
For that, animals were maintained in a Type II biosafety
facility. The experiment lasted the minimum period of
time (42 days) enough for the vaccinated animals to de-
velop a detectable immune response of a similar level to
the one found in the field.
Inactivated BoHV-1ΔgEβgal displayed similar virus
shedding period and titers as those recorded for the
wild-type-based inactivated vaccine. These results are
comparable to those communicated by Bosch et al. [21]
and Kaashoek et al. [16] and ourselves [26]. A thorough
evaluation of the specific BoHV-1 humoral and cellular
immune responses demonstrates the antigenic integrity of
the glycoprotein E-deleted bovine herpesvirus type 1
strain. Importantly, BoHV-1ΔgEβgal-vaccinated bovines
were easily differentiated from BoHV-1 LA-vaccinated an-
imals, mock-vaccinated and BoHV-1-challenged animals,
indicating the efficacy of inactivated BoHV-1ΔgEβgal as a
marker vaccine.
BoHV-1ΔgEβgal as a LAV was highly immunogenic,
inducing a humoral immune response comparable to
those induced by previous BoHV-1 attenuated vaccines
[2,11,15,18,32,33].
Significantly, BoHV-1ΔgEβgal induced an antibody re-
sponse that could easily be differentiated from that elic-
ited by parental wild-type BoHV-1 LA virus. During the
post-vaccination period of both inactivated and LAV
BoHV-1ΔgEβgal studies, no anti-gE antibodies were de-
tected until after challenge with the wild-type BoHV-1
virus, thus demonstrating its suitability as a DIVA
marker vaccine.
The aim of the present work was to evaluate safety in
terms of vertical or horizontal spreading of a novel
BoHV-1 marker strain. Thus, an extremely high dose of
BoHV-1ΔgEβgal was used for immunization. The mini-
mum immunogenic and protective dose for its use in a
commercial vaccine will be determined in future expe-
riments. Live BoHV-1ΔgEβgal exhibits a noticeable at-
tenuation, no virus was detected in nasal secretions
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was better than other BoHV-1 recombinant strains con-
taining gE deletions [2,32,33], which showed virus shed-
ding from 104 to 106 TCID50/ml in a period from 6 to
8 days post-immunization. In order be considered safe,
a LAV should not perpetuate in the cattle population
[34]. Strube et al. reported that although the gE-deleted
IBR vaccine strain Difivac® may be shed by immunized
animals, it has a limited ability to pass from animal to
animal [35]. In our study, although a high dose of virus
was used to inoculate the animals (108.25 TCID50/ml),
no BoHV-1ΔgEβgal was recovered from the nasal secre-
tions of vaccinated or sentinel animals although both
groups cohabitated up to the 42 dpv. Furthermore,
BoHV-1ΔgEβgal IV immunized pregnant cows did not
transmit the recombinant virus to their newborns.
The IV route of inoculation is usually considered the
most aggressive immunization or infection method dur-
ing pregnancy, since it represents a direct access of any
pathogen or drug to critical organs (ie, spleen, liver,
lungs), and thus is the route of choice to test drug safety.
Safety assays performed in pregnant cows demonstrated
that vertical spreading of BoHV-1ΔgEβgal was null and
newborn calves born to infected mothers showed detect-
able levels of anti-BoHV-1 maternal antibodies by day 9
after birth.
Two important features should be considered when
comparing our results to those from Mars et al. their
mutant virus did not carry a deletion of the complete
gE ORF and cattle used in that study were 4 weeks-old
calves [34]. Similar results were reported by van der
Poel et al. using a BoHV-1ΔgE strain inoculated intra-
muscularly [36]. Once in the animals, BoHV-1ΔgEβgal
showed absence of horizontal and vertical spreading
most probably related to the low replication levels of
the recombinant strain, although this should be clari-
fied by future pathogenicity, latency and reactivation
experiments.
Protection against challenge induced by the recom-
binant virus was evaluated in terms of reduction of
clinical disease and, most importantly, reduction of
shedding of challenge virus. Only half of the IM- or IN-
vaccinated and challenged animals excreted virus, with
titer values of 102.6 to 105.5 TCID50/ml during a 2 day
period. The levels of excreted virus in a post-challenge
period were similar to those reported by other authors
[2,11,15,17,18,33,35]. Even though animals vaccinated
with inactivated BoHV-1ΔgEβgal showed higher VN ti-
ters than those immunized with live attenuated virus
(IM or IN routes), no differences were found on virus
shedding following BoHV-1 viral challenge. Remarkably,
despite the fact that no detectable VN titers were found
in circulating blood, the animals vaccinated by intrana-
sal route with BoHV-1ΔgEβgal virus were protectedagainst challenge. This result may probably related
to the local induction of virus-specific immunity, as
mentioned for individuals immunized with the inacti-
vated BoHV-1ΔgEβgal virus, but needs to be further
confirmed.
As a whole, our results showed that the BoHV-
1ΔgEβgal may be used both as an inactivated immuno-
gen or as a LAV against BoHV-1 infection in cattle. This
recombinant virus elicited an efficient immune response
with both strategies, which can protect animals from
challenge with virulent wild-type BoHV-1 and may be
serologically differentiated from that induced by wild-
type virus. Safety assays demonstrated that BoHV-
1ΔgEβgal was not horizontally or vertically transmitted
when administered as a LAV, even when very high doses
were utilized. The minimum immunogenic and protect-
ive dose for its use in a commercial vaccine will be
determined in future experiments.
Conclusion
The BoHV-1ΔgEβgal strain is completely safe in terms
of transmission to unvaccinated animals or environmen-
tal dissemination; BoHV-1ΔgEβgal is absolutely innocu-
ous in pregnant cows and behaves as an attenuated
BoHV1 strain in calves. Also, BoHV-1ΔgEβgal is protect-
ive against viral challenge and acts as an efficacious
marker vaccine, since no antibodies were detected against
gE protein during the post-vaccination period. Therefore,
the new vaccine strain described here provides a useful
combination of safety, attenuation, immunogenicity and
DIVA capability.
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